HUTCHMED (China) Limited

和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2)(l) OF THE LISTING RULES

This announcement is made by HUTCHMED (China) Limited (the "Company", together with its subsidiaries, the "Group") pursuant to Rules 13.51B(2) and 13.51(2)(l) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The board of directors of the Company (the "Board") was notified by Dr Dan Eldar, Chairman and Non-executive Director of the Company, that S.D. Sight Diagnostics Ltd. ("S.D. Sight"), a company of which Dr Eldar was formerly a director, had become subject to insolvency proceedings in Israel.

As the Company understands, S.D. Sight is an Israeli private company incorporated in Tel Aviv, Israel and is a medical device company developing a platform for diagnosing blood diseases using computer vision technology. Dr Eldar was a director of S.D. Sight from 20 December 2018 to 18 March 2026. Hutchison Water Israel E.P.C Ltd, of which Dr Eldar is an executive director, made an investment of approximately 9.98% in S.D. Sight and nominated Dr Eldar as a director to the board of S.D. Sight. Neither Hutchison Water Israel E.P.C Ltd nor S.D. Sight is a member of the Group.

Based on the information available to the Company, an application for commencement of insolvency proceedings in respect of S.D. Sight was filed on 12 April 2026, with the Tel Aviv-Jaffa District Court issuing an order for commencement of proceedings on 24 May 2026, and a trustee appointed on 28 May 2026. The insolvency proceedings remained ongoing. The outcome of the proceedings is not known to the Company as at the date of this announcement.

The amount involved in the proceedings, based on public information made available by the Insolvency Proceedings Commissioner in Israel, is approximately NIS3,057,876 (equivalent to approximately US$1,019,292).

As the commencement of the insolvency proceedings in respect of S.D. Sight and the appointment of the trustee occurred within 12 months after Dr Eldar ceased to act as a director of S.D. Sight, the above information is disclosed by the Company pursuant to Rules 13.51B(2) and 13.51(2)(l) of the Listing Rules, as a change of information regarding Dr Eldar.

As the insolvency proceedings do not involve the Group or its businesses, the Board is of the opinion that it does not have any impact on the businesses and operations of the Group.

Save as disclosed above, there is no other information concerning the above change that needs to be brought to the attention of the shareholders of the Company.

By Order of the Board

Edith Shih
Non-executive Director and Company Secretary

Hong Kong, August 18, 2026

As at the date of this announcement, the Directors of the Company are:

Chairman and Non-executive Director:
Dr Dan ELDAR

Executive Directors:
Dr Weiguo SU
(Chief Executive Officer and Chief Scientific Officer)
Mr CHENG Chig Fung, Johnny
(Acting Chief Executive Officer and Chief Financial Officer)

Non-executive Directors:
Ms Edith SHIH
Ms Ling YANG

Independent Non-executive Directors:
Dr Renu BHATIA
(Senior and Lead Independent Non-executive Director)
Dr Chaohong HU
Professor TAN Shao Weng, Daniel
Mr WONG Tak Wai